Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enbrel liquid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Etanercept liquid | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 50 mg Etanercept | DRUG | 50 mg Etanercept liquid injected SC once weekly using prefilled syringes |
| Enbrel liquid | DRUG | 50 mg Etanercept liquid injected SC once weekly using prefilled syringes |
Inclusion Criteria: * 18 years of age or older * Must be able to self-inject or have someone who can do so for them * Should have Rheumatoid Arthritis per ARA criteria and screening lab results per predefined value Exclusion Criteria: * Any prior biologic therapy for inflammatory disease * Any pr...
Top 20 of 28 competitors
Enbrel liquid is used for Rheumatoid Arthritis. It is an investigational therapy being developed by Amgen Inc. for this condition. The drug is currently in Phase 3 clinical development, meaning it has not yet been approved and is still being studied for safety and efficacy in patients.
Enbrel liquid is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. Amgen is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of Rheumatoid Arthritis.
Enbrel liquid is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 3 trial for Enbrel liquid has been completed, with a total enrollment of 447 participants.
Enbrel liquid has one completed clinical trial, identified by the NCT number NCT00249041. This Phase 3 study, titled 'Enbrel Liquid Immunogenicity Protocol,' enrolled 447 participants with Rheumatoid Arthritis. The trial was uncontrolled and did not use randomization or double-blinding.
Enbrel liquid is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for Rheumatoid Arthritis. The completed Phase 3 trial, NCT00249041, has finished, but the drug has not yet received regulatory approval.